Exosome gene therapy platform allows highly-specific, targeted delivery of regulatory RNA to shut down cancer growth with limited toxicity
Montreal, April 15 2019 – TAVEC Pharmaceuticals, (TAVEC) announced today the completion of a worldwide, exclusive license with The Johns Hopkins University for exosome mediated gene therapy to treat cancer and other diseases. Terms of the license agreement were not disclosed.
TAVEC’s exosome mediated technology enables delivery of powerful regulating genes known as microRNA directly to cancer cells to disrupt growth and metastasis. Exosomes are small, naturally occurring vesicles which can be grown to enable highly-specific targeting of cancer cells to unleash their payload.
“We believe exosome delivery of cancer disruptive microRNA has broad applications across cancer indications as either a mono-therapy or in combination with other immune-therapy platforms” said Robert G. McNeil, CEO of TAVEC.
The ability to deliver RNA gene therapy with specific targeting to cancer cells represents an important addition to the combination therapies required to shut-down cancer growth and metastasis. The stromal-cell derived exosome preparations developed by Professor Florin Selaru and colleagues at Johns Hopkins have the particular advantages of limited toxicity, selective delivery of tumor-suppressive molecules to cancer cells, reduced tumor growth, and prolonged survival.
About TAVEC’s Exosome RNA Therapy
At TAVEC, we load key regulatory molecules, called micro-ribonucleic acids or “miRNA” into the body’s natural exosome delivery system to create powerful anti-cancer therapeutics. Our exosomes are prepared to specifically target cancer cells and deliver their genetic payloads to effect maximum disruption on cancer growth. miRNAs are powerful “non-coding” molecules that have the ability to shut-down or disrupt the key genetic messages responsible for cancer growth and metastasis. Exosomes are small, naturally formed vesicles secreted by all human cell types into circulation. Because they are normally produced by the body, exosomes are non-immunogenic, meaning they do not cause an immune response or “rejection” and act as ideal circulating delivery vehicles. Exosomes have a lipid coating that protects their cargo from RNA-degrading enzymes in blood and other body fluids. We produce specialized types of exosomes that are selectively taken up by cancer cells and can be used to deliver tumor suppressive miRNAs and other disruptive molecules to cancer cells with minimal effects on normal tissue.